Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism.

Saved in:
Bibliographic Details
Title: Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism.
Authors: Overdijk MB; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Strumane K; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Beurskens FJ; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Ortiz Buijsse A; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Vermot-Desroches C; iDD biotech, Lyon, France., Vuillermoz BS; iDD biotech, Lyon, France., Kroes T; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., de Jong B; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Hoevenaars N; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Hibbert RG; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Lingnau A; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Forssmann U; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Schuurman J; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Parren PWHI; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.; Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands., de Jong RN; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton., Breij ECW; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton. ebj@genmab.com.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2020 Oct; Vol. 19 (10), pp. 2126-2138. Date of Electronic Publication: 2020 Aug 26.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32847982
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Overdijk+MB%22">Overdijk MB</searchLink>; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.<br /><searchLink fieldCode="AU" term="%22Strumane+K%22">Strumane K</searchLink>; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.<br /><searchLink fieldCode="AU" term="%22Beurskens+FJ%22">Beurskens FJ</searchLink>; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.<br /><searchLink fieldCode="AU" term="%22Ortiz+Buijsse+A%22">Ortiz Buijsse A</searchLink>; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.<br /><searchLink fieldCode="AU" term="%22Vermot-Desroches+C%22">Vermot-Desroches C</searchLink>; iDD biotech, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Vuillermoz+BS%22">Vuillermoz BS</searchLink>; iDD biotech, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Kroes+T%22">Kroes T</searchLink>; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.<br /><searchLink fieldCode="AU" term="%22de+Jong+B%22">de Jong B</searchLink>; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.<br /><searchLink fieldCode="AU" term="%22Hoevenaars+N%22">Hoevenaars N</searchLink>; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.<br /><searchLink fieldCode="AU" term="%22Hibbert+RG%22">Hibbert RG</searchLink>; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.<br /><searchLink fieldCode="AU" term="%22Lingnau+A%22">Lingnau A</searchLink>; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.<br /><searchLink fieldCode="AU" term="%22Forssmann+U%22">Forssmann U</searchLink>; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.<br /><searchLink fieldCode="AU" term="%22Schuurman+J%22">Schuurman J</searchLink>; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.<br /><searchLink fieldCode="AU" term="%22Parren+PWHI%22">Parren PWHI</searchLink>; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.; Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Jong+RN%22">de Jong RN</searchLink>; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton.<br /><searchLink fieldCode="AU" term="%22Breij+ECW%22">Breij ECW</searchLink>; Genmab, Utrecht, the Netherlands, Copenhagen, Denmark, Princeton. ebj@genmab.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2020 Oct; Vol. 19 (10), pp. 2126-2138. <i>Date of Electronic Publication: </i>2020 Aug 26.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32847982
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-20-0044
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2126
    Titles:
      – TitleFull: Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Overdijk MB
      – PersonEntity:
          Name:
            NameFull: Strumane K
      – PersonEntity:
          Name:
            NameFull: Beurskens FJ
      – PersonEntity:
          Name:
            NameFull: Ortiz Buijsse A
      – PersonEntity:
          Name:
            NameFull: Vermot-Desroches C
      – PersonEntity:
          Name:
            NameFull: Vuillermoz BS
      – PersonEntity:
          Name:
            NameFull: Kroes T
      – PersonEntity:
          Name:
            NameFull: de Jong B
      – PersonEntity:
          Name:
            NameFull: Hoevenaars N
      – PersonEntity:
          Name:
            NameFull: Hibbert RG
      – PersonEntity:
          Name:
            NameFull: Lingnau A
      – PersonEntity:
          Name:
            NameFull: Forssmann U
      – PersonEntity:
          Name:
            NameFull: Schuurman J
      – PersonEntity:
          Name:
            NameFull: Parren PWHI
      – PersonEntity:
          Name:
            NameFull: de Jong RN
      – PersonEntity:
          Name:
            NameFull: Breij ECW
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2020 Oct
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Numbering:
            – Type: volume
              Value: 19
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1